What Happened in MP's Cough Syrup Tragedy? Ranganathan Taken to Parasia Court
Click to start listening
Synopsis
The tragic cough syrup incident in Madhya Pradesh has led to widespread outrage and legal action against Ranganathan Govindhan, owner of Sresan Pharmaceuticals. With 25 children dead, the investigation is intensifying, highlighting the urgent need for stronger pharmaceutical regulations.
Key Takeaways
- 25 children died due to toxic cough syrup.
- Ranganathan Govindhan was arrested after fleeing.
- Cough syrup 'Coldrif' contained diethylene glycol.
- Public protests are demanding accountability.
- Investigation is ongoing to prevent future tragedies.
Bhopal/Chhindwara, Oct 10 (NationPress) The Special Investigation Team (SIT) of Madhya Pradesh Police has brought Ranganathan Govindhan, the owner of Tamil Nadu-based Sresan Pharmaceuticals, before the Parasia (Chhindwara) court on Friday, related to the tragic deaths of 25 children because of a toxic cough syrup.
Govindhan, who had a ₹20,000 bounty on his head, was captured in Chennai after he and his wife fled following the incident.
As reported by police sources, he is set to be presented in the Parasia court at 2 p.m., where the SIT will request his remand.
The investigative team, consisting of 12 members, including six officers, was sent to Tamil Nadu earlier this week to track Govindhan's movements, culminating in his arrest on Wednesday.
Authorities were concerned he might attempt to flee overseas, as his children live abroad. He has now been transported to Parasia in Chhindwara for further questioning.
The cough syrup in question, named 'Coldrif', was discovered to contain dangerously elevated levels of diethylene glycol, a toxic substance.
In parallel, the state government has ordered post-mortem examinations for three of the deceased children, while forensic teams are diligently working to collect technical evidence to bolster the case.
Additionally, the state government has suspended certain officials and arrested Praveen Soni in Parasia for prescribing the hazardous cough syrup 'Coldrif'.
However, the Indian Medical Association has protested Soni's arrest, asserting that doctors bear no responsibility for the manufacturing of medicines.
According to its representatives, the Association is exploring options to challenge Dr. Soni's arrest in the High Court. Public outrage over the incident has surged.
Workers from the Samajwadi Party demonstrated at Malviya Chowk, calling for the resignation of state Health Minister Rajendra Shukla.
Protesters have accused the government of negligence, blaming it for the loss of innocent lives.
Posters of the minister were displayed on the road as demonstrators demanded accountability. This tragic event has ignited widespread concern and calls for enhanced pharmaceutical regulation, as investigations continue into this grievous failure in drug safety.
Point of View
I stand with the nation in demanding justice for the families affected by the tragic cough syrup incident. This situation underscores a critical need for pharmaceutical accountability and the safety of our children. We must hold those responsible accountable while ensuring that such a tragedy never occurs again.
NationPress
11/10/2025
Frequently Asked Questions
What caused the deaths of the children?
The deaths were attributed to a toxic cough syrup named 'Coldrif', which contained dangerously high levels of diethylene glycol.
Who is Ranganathan Govindhan?
Ranganathan Govindhan is the owner of Sresan Pharmaceuticals, the company linked to the toxic cough syrup involved in the tragedy.
What actions have been taken against those responsible?
Authorities have arrested Praveen Soni for prescribing the toxic syrup and suspended certain officials while conducting ongoing investigations.
What are the public's reactions to this incident?
Public outrage has intensified, with protests demanding accountability from government officials, including calls for the resignation of the state Health Minister.
What measures are being taken to prevent future incidents?
The incident has sparked calls for stricter pharmaceutical regulations and oversight to ensure drug safety and accountability in the industry.
